BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Plasticell Delivers Differentiation Protocols to Stemnion, Inc.


8/3/2011 9:47:25 AM

August 03, 2011 -- Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced the successful completion of a collaboration with Stemnion, Inc. (Pittsburgh, PA), a US biotechnology company focused on the applications of stem cells derived from human placentas.

Plasticell used its flagship technology CombiCult™ to discover multiple novel, serum-free protocols that direct the differentiation of Stemnion’s stem cells into hard-to-obtain lineages. The protocols were ranked using Plasticell’s Ariadne™ bioinformatics software and subsequently validated by Stemnion scientists.

“Using CombiCult™’s combinatorial technology, we identified several differentiation protocols for our cells at a fraction of the time, resources and cost compared to conventional trial-and-error methods,” said Randall Rupp, Vice-President, Manufacturing and Development, Stemnion, Inc.

“This project once again demonstrates the flexibility and the power of CombiCult™ to push the differentiation of adult stem cells into various lineages,” said Dr. Lilian Hook, Director of Research at Plasticell. “Stemnion provided us with a challenge that is typical of adult stem cell R&D programmes, however this project was particularly interesting on several fronts, including, for the first time, utilising placenta-derived stem cells as the starting cell-type.”

ABOUT STEMNION

Stemnion, Inc. Is a biomedical regenerative medicine company developing novel cell-based therapeutic products. Stemnion, Inc. is based in Pittsburgh, Pennsylavania (USA).

About Plasticell

Plasticell is a biotechnology company that specialises in using massively parallel screens to differentiate stem cells.

The company’s proprietary technology, Combinatorial Cell Culture™ (CombiCultTM), allows testing of cell culture variables in random combinations to discover optimal laboratory protocols for the differentiation of adult or pluripotent stem cells.

Plasticell provides services to, and forms strategic alliances with, industry partners to produce high value cell lines for drug discovery and cell therapy applications.

For more information visit the Plasticell website: www.plasticell.co.uk

For confidential technical enquiries please contact Dr Lilian Hook on 00 44 7811 168 177 or email: lilian@plasticell.co.uk

For media enquiries, please contact Tristan Jervis on 00 44 207 861 3019 or e-mail: t.jervis@defacto.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES